Abstract
Background Early life adversity (ELA) is associated with altered insulin signaling and altered EF behaviors, in a potentially sex-specific manner. Considering the high co-morbidity between altered metabolism and executive function (EF) problems, we hypothesized that the genetic background associated with altered fasting insulin (FI) and EF could be shared
Methods Our study used conjunctional false discovery rate (ConjFDR) to identify the shared genetic architecture between FI and two EFs: impulsivity and attention deficit-hyperactivity disorder (ADHD). We identified the polygenic risk score (PRS) threshold from a FI genome-wide association study (GWAS) that best predicted insulin levels in male and female ALSPAC children [Nmales=1,901, Nfemales=1,834; pt-intial-males= 0.05 (11,121 SNPs), pt-intial-females= 0.15 (27,202 SNPs)], further refining it to only include SNPs significantly associated with insulin levels in children [NSNP-males= 635 SNPs, NSNP-females = 1,449 SNPs]. A phenome-wide association study (PheWAS) was also run to identify EFs associated with the interaction between the refined PRS (rPRS) and early adversity. To investigate the presence of a direct causal relationship between FI and impulsivity in the presence of adversity, we applied mendelian randomization (MR)
Results ConjFDR suggested that environmental factors could be involved in the association between insulin and EFs, as there was no shared genetic background. PheWAS highlighted impulsivity and attention-related outcomes in interaction models between FI rPRS and early adversity. Finally, two-sample MR suggested a causal association between higher fasting insulin levels and impulsive behavior, specifically in females exposed to adversity (p < 0.001). Overall, a sex-specific impulsivity GWAS demonstrated that MYT1L and TSSC1, genes that are associated with motor impulsivity, were enriched only in females.
Conclusions Our study solidifies the evidence that the relationship between high FI and EF is not direct, but rather interacting with ELA exposure, especially in females.
Early life adversity is associated with alterations in insulin signaling and executive functioning behaviors.
We report a causal association between high fasting insulin and increased impulsivity in females exposed to adversity.
Our findings also support the idea that fasting insulin moderates the long-term effects of early life adversity on executive functions in females.
This research provides insights into the mechanisms by which insulin moderates the effects of early life adversity on executive function disorders and informs the development of potential interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by: Canadian Institutes of Health Research (CIHR, PJT-166066, PPS and IP), the JPB Foundation through a grant to the JPB Research Network on Toxic Stress: A Project of the Center on the Developing Child at Harvard University, Fonds de recherche du Quebec – Sante (FRQS to AB and PPS), awarded for the project: Les variations de la function de linsuline modulent ladversite au debut de la vie sur les compartements lies a la dopamine mesocorticolimbique. Finally, this research was also supported by an award from the McGill-Douglas Max Planck Institute of Psychiatry International Collaborative Initiative in Adversity and Mental Health, an international partnership funded by the Healthy Brains for Healthy Lives initiative. The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); ALSPAC GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. The authors declare no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for the study was obtained from the ALSPAC Ethics and Law Committee and the local research ethics committees. Approval for the MAVAN project was obtained by the ethics committees and university affiliates (McGill University and Universite de Montreal, the Royal Victoria Hospital, Jewish General Hospital, Centre hospitalier de lUniversite de Montreal and Hopital Maisonneuve-Rosemount) and St. Josephs Hospital and McMaster University, Hamilton, Ontario, Canada. This study was approved by the National University Hospital and KK Womens and Childrens Hospital, National Healthcare Group Domain Specific Review Board (NHG DSRB Ref D/09/021) and Sing Health Centralized Institutional Review Board (CIRB Ref 2018/2767). The institutional review board of the University of California, San Diego centralized the approval for data collection from ABCD. Approval for the UK Biobank was obtained by the North West Multicentre Research 580 Ethics Committee, the National Information Governance Board for Health and Social Care and the Community Health Index Advisory Group.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data in the present work are contained in the Supplementary Materials.
